In agreement, prostasomal CD59, which is released by prostate cancer cells to a considerably higher degree than by normal cells, was shown to be transferred to rabbit erythrocytes (lacking CD59) in vitro and to foster inhibition of complement (C5b-9)-mediated lysis more efficiently in comparison to that released from non-malignant cells [41]. Here, CD59 is linked to prostate cancer.